<?xml version='1.0' encoding='utf-8'?>
<document id="22900583"><sentence text="Pharmacokinetic interaction between prasugrel and ritonavir in healthy volunteers."><entity charOffset="36-45" id="DDI-PubMed.22900583.s1.e0" text="prasugrel" /><entity charOffset="50-59" id="DDI-PubMed.22900583.s1.e1" text="ritonavir" /><pair ddi="false" e1="DDI-PubMed.22900583.s1.e0" e2="DDI-PubMed.22900583.s1.e0" /><pair ddi="false" e1="DDI-PubMed.22900583.s1.e0" e2="DDI-PubMed.22900583.s1.e1" /></sentence><sentence text="The new anti-aggregating agent prasugrel is bioactivated by cytochromes P450 (CYP) 3A and 2B6"><entity charOffset="31-40" id="DDI-PubMed.22900583.s2.e0" text="prasugrel" /></sentence><sentence text=" Ritonavir is a potent CYP3A inhibitor and was shown in vitro as a CYP2B6 inhibitor"><entity charOffset="1-10" id="DDI-PubMed.22900583.s3.e0" text="Ritonavir" /></sentence><sentence text=" The aim of this open-label cross-over study was to assess the effect of ritonavir on prasugrel active metabolite (prasugrel AM) pharmacokinetics in healthy volunteers"><entity charOffset="73-82" id="DDI-PubMed.22900583.s4.e0" text="ritonavir" /><entity charOffset="86-95" id="DDI-PubMed.22900583.s4.e1" text="prasugrel" /><entity charOffset="115-124" id="DDI-PubMed.22900583.s4.e2" text="prasugrel" /><pair ddi="false" e1="DDI-PubMed.22900583.s4.e0" e2="DDI-PubMed.22900583.s4.e0" /><pair ddi="false" e1="DDI-PubMed.22900583.s4.e0" e2="DDI-PubMed.22900583.s4.e1" /><pair ddi="false" e1="DDI-PubMed.22900583.s4.e0" e2="DDI-PubMed.22900583.s4.e2" /><pair ddi="false" e1="DDI-PubMed.22900583.s4.e1" e2="DDI-PubMed.22900583.s4.e1" /><pair ddi="false" e1="DDI-PubMed.22900583.s4.e1" e2="DDI-PubMed.22900583.s4.e2" /></sentence><sentence text=" Ten healthy male volunteers received 10 mg prasugrel"><entity charOffset="44-53" id="DDI-PubMed.22900583.s5.e0" text="prasugrel" /></sentence><sentence text=" After at least a week washout, they received 100 mg ritonavir, followed by 10 mg prasugrel 2 hr later"><entity charOffset="53-62" id="DDI-PubMed.22900583.s6.e0" text="ritonavir" /><entity charOffset="82-91" id="DDI-PubMed.22900583.s6.e1" text="prasugrel" /><pair ddi="false" e1="DDI-PubMed.22900583.s6.e0" e2="DDI-PubMed.22900583.s6.e0" /><pair ddi="false" e1="DDI-PubMed.22900583.s6.e0" e2="DDI-PubMed.22900583.s6.e1" /></sentence><sentence text=" We used dried blood spot sampling method to monitor prasugrel AM pharmacokinetics (C(max) , t(1/2) , t(max) , AUC(0-6 hr) ) at 0, 0" /><sentence text="25, 0" /><sentence text="5, 1, 1" /><sentence text="5, 2, 4 and 6 hr after prasugrel administration" /><sentence text=" A 'cocktail' approach was used to measure CYP2B6, 2C9, 2C19 and 3A activities" /><sentence text=" In the presence of ritonavir, prasugrel AM C(max)  and AUC were decreased by 45% (mean ratio: 0"><entity charOffset="20-29" id="DDI-PubMed.22900583.s12.e0" text="ritonavir" /><entity charOffset="31-40" id="DDI-PubMed.22900583.s12.e1" text="prasugrel" /><pair ddi="false" e1="DDI-PubMed.22900583.s12.e0" e2="DDI-PubMed.22900583.s12.e0" /><pair ddi="false" e1="DDI-PubMed.22900583.s12.e0" e2="DDI-PubMed.22900583.s12.e1" /></sentence><sentence text="55, CI 90%: 0" /><sentence text="40-0" /><sentence text="7, p = 0" /><sentence text="007) and 38% (mean ratio: 0" /><sentence text="62, CI 90%: 0" /><sentence text="54-0" /><sentence text="7, p = 0" /><sentence text="005), respectively, while t(1/2)  and t(max)  were not affected" /><sentence text=" Midazolam metabolic ratio (MR) dramatically decreased in presence of ritonavir (6"><entity charOffset="1-10" id="DDI-PubMed.22900583.s21.e0" text="Midazolam" /><entity charOffset="70-79" id="DDI-PubMed.22900583.s21.e1" text="ritonavir" /><pair ddi="false" e1="DDI-PubMed.22900583.s21.e0" e2="DDI-PubMed.22900583.s21.e0" /><pair ddi="false" e1="DDI-PubMed.22900583.s21.e0" e2="DDI-PubMed.22900583.s21.e1" /></sentence><sentence text="7 ± 2" /><sentence text="6 versus 0" /><sentence text="13 ± 0" /><sentence text="07) reflecting an almost complete inhibition of CYP3A4, whereas omeprazole, flurbiprofen and bupropion MR were not affected"><entity charOffset="64-74" id="DDI-PubMed.22900583.s25.e0" text="omeprazole" /><entity charOffset="76-88" id="DDI-PubMed.22900583.s25.e1" text="flurbiprofen" /><entity charOffset="93-102" id="DDI-PubMed.22900583.s25.e2" text="bupropion" /><pair ddi="false" e1="DDI-PubMed.22900583.s25.e0" e2="DDI-PubMed.22900583.s25.e0" /><pair ddi="false" e1="DDI-PubMed.22900583.s25.e0" e2="DDI-PubMed.22900583.s25.e1" /><pair ddi="false" e1="DDI-PubMed.22900583.s25.e0" e2="DDI-PubMed.22900583.s25.e2" /><pair ddi="false" e1="DDI-PubMed.22900583.s25.e1" e2="DDI-PubMed.22900583.s25.e1" /><pair ddi="false" e1="DDI-PubMed.22900583.s25.e1" e2="DDI-PubMed.22900583.s25.e2" /></sentence><sentence text=" These data demonstrate that ritonavir is able to block prasugrel CYP3A4 bioactivation"><entity charOffset="29-38" id="DDI-PubMed.22900583.s26.e0" text="ritonavir" /><entity charOffset="56-65" id="DDI-PubMed.22900583.s26.e1" text="prasugrel" /><pair ddi="false" e1="DDI-PubMed.22900583.s26.e0" e2="DDI-PubMed.22900583.s26.e0" /><pair ddi="false" e1="DDI-PubMed.22900583.s26.e0" e2="DDI-PubMed.22900583.s26.e1" /></sentence><sentence text=" This CYP-mediated drug-drug interaction might lead to a significant reduction of prasugrel efficacy in HIV-infected patients with acute coronary syndrome" /><sentence text="" /></document>